Engineered T Cells for Treating B-Cell Chronic Lymphocytic Leukaemia
Author Information
Author(s): Philipp Koehler, Patrick Schmidt, Andreas A. Hombach, Michael Hallek, Hinrich Abken
Primary Institution: University Hospital Cologne
Hypothesis
Can genetically engineered T cells effectively target and eliminate B-CLL cells?
Conclusion
Genetically engineered T cells can effectively target and eliminate B-CLL cells, but they also lead to the depletion of healthy B-cells.
Supporting Evidence
- CAR-engineered T cells can effectively target CD19 on B-CLL cells.
- Redirected T cells can eliminate CD19+ leukaemia cells with high efficiency.
- Targeting CD19 is ideal for redirected therapy of B-CLL.
Takeaway
Scientists are using special T cells that can find and destroy cancer cells in patients with a type of blood cancer called B-CLL, but these T cells can also harm healthy cells.
Methodology
The study discusses the use of CAR-engineered T cells to target CD19 on B-CLL cells, including preclinical and clinical data.
Limitations
The therapy can lead to the elimination of healthy B-cells, and the long-term effects of T cell persistence and safety are still under investigation.
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website